On August 24, 2022 ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, reported that L1 Capital Global Opportunities Master Fund ("L1") has exercised Options over 1,000,000 new ordinary shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £50,000 (Press release, ImmuPharma, AUG 24, 2022, View Source [SID1234618603]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New Ordinary Shares and Admission

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company’s existing issued Ordinary Shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Tuesday 30 August 2022.

The New Ordinary Shares represent 0.30% of the Company’s enlarged issued share capital.

Total Shares in Issue

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company’s total issued share capital will consist of 328,403,115 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.

On August 24, 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, reported its participation in the following upcoming conferences (Press release, Ensysce Biosciences, AUG 24, 2022, View Source [SID1234618600]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PAINWeek Conference 2022, September 6 – September 9, 2022, in Las Vegas, NV. Dr. Lynn Kirkpatrick, Chief Executive Officer, to chair a symposium and panel, entitled, "Severe Pain, Strategic Perspectives." The symposium will be held on September 9th from 12:30 p.m. – 1:30 p.m. Pacific time.
H.C. Wainwright 24th Annual Global Investment Conference, September 12 – September 14, 2022, at the Lotte New York Palace Hotel, New York, NY.
Lake Street 6th Annual Best Ideas Growth Conference, Wednesday, September 14, 2022, at The Yale Club, New York, NY.
New Product Planning Summit, September 19-20, 2022, in Boston, MA. Geoff Birkett, Chief Commercial Officer, to chair the meeting and speak on his prior experience launching several major neuroscience and pain products.
The Company’s Chief Executive Officer, Dr. Lynn Kirkpatrick, and Chief Financial Officer, Dave Humphrey, will be available for one-on-one meetings during both the H.C. Wainwright and Lake Street conferences. For more information about the events or to schedule a one-on-one meeting with Ensysce’s management, please contact Ensysce’s Investor Relations at [email protected].

On August 24, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, reported that the company is scheduled to present at the following September investor conferences (Press release, Agios Pharmaceuticals, AUG 24, 2022, View Source [SID1234618599]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and
Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m. ET.
Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

On August 24, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC) (Press release, Sellas Life Sciences, AUG 24, 2022, View Source [SID1234618598]). The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NEPC, an aggressive variant of prostate cancer, is a rapidly growing indication which arises as a result of otherwise successful treatment of advanced prostate cancer. In up to 15 to 20 percent of patients treated with hormonal therapies for prostate adenocarcinoma, small-cell prostate cancer may develop in later stages of prostate cancer progression. This histologic transformation occurs as a mechanism of treatment resistance. Aggressive NEPC represents a lethal endpoint in the progression of prostate cancer from prostate adenocarcinoma to castration-resistant prostate cancer (CRPC) to NEPC. Median survival for NEPC patients whose cancer arose from prior prostate adenocarcinoma is estimated at only 5.4 months.

The conversion to NEPC is associated with recurrent genetic lesions including mutation or deletion of RB1 and TP53 as well as the overexpression and genomic amplification of MYCN. SELLAS believes that all forms of MYC may be susceptible to CDK9 inhibition and the data from the in vitro study, conducted at an independent, third-party contract research organization, Translational Drug Development (TD2), supported this supposition, resulting in 38 nM median IC50 value.

"We are very excited with this first confirmation of our hypothesis that GFH009 could address NEPC, a rapidly growing indication," said Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS. "About one in eight men will be diagnosed with prostate cancer during his lifetime and any significant change in the course of treatment for this cancer has potential for outsized consequences."

About Translational Drug Development (TD2)
TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

On August 24, 2022 PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, reported that the Company will present at the 2022 Wells Fargo Healthcare Conference and the Baird’s 2022 Global Healthcare Conference (Press release, PerkinElmer, AUG 24, 2022, View Source [SID1234618597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Wells Fargo Healthcare Conference – Boston, MA
Wednesday, September 7, 2022
8:00 a.m. ET
Registration link

Baird’s 2022 Global Healthcare Conference – New York, NY
Tuesday, September 13, 2022
10:50 a.m. ET
Registration link

Prahlad Singh, president and chief executive officer, will provide an overview of the Company and its strategic priorities at both conferences during 30-minute fireside chats.

Live audio webcasts will be available on the Investors section of the Company’s website at www.perkinelmer.com. A replay of each presentation will also be posted on the PerkinElmer website after each event and remain available for 90 days following.